Aurobindo Pharma’s subsidiary, CuraTeQ Biologics, has mutually agreed to terminate its agreement with BioFactura Inc, USA, regarding the development of BFI-751, an ustekinumab biosimilar product. The termination, effective December 27, 2025, aligns with CuraTeQ’s strategic portfolio prioritization. The company does not expect the decision to have a significant impact on its overall biosimilars strategy.
Agreement Termination Details
CuraTeQ Biologics Private Limited, a wholly owned subsidiary of Aurobindo Pharma, terminated its agreement with BioFactura Inc, USA, concerning the development of BFI-751, a proposed biosimilar to Stelara (Ustekinumab). The original agreement, aimed at commercializing BFI-751, has been terminated as of December 27, 2025.
Reasoning and Strategic Impact
The decision to terminate the agreement aligns with CuraTeQ’s strategic portfolio prioritization. The company stated that the termination is not expected to have a material impact on Aurobindo Pharma’s overall biosimilars strategy. BioFactura was expected to receive license fees based on milestones achieved leading to commercialization, while CuraTeQ would retain global manufacturing rights.
Original Agreement Purpose
The initial agreement with BioFactura was intended to commercialize BFI-751, a proposed biosimilar to Stelara (Ustekinumab). As per the original agreement, BioFactura was slated to receive license fees spread across different milestones leading to commercialization in regulated markets, while CuraTeQ was to obtain global manufacturing rights. The agreement had been executed on July 7, 2023.
Source: BSE
